BridgeMD
The Impact of a Parasternal Block on Pain After Open-Heart Surgery: A Multicenter Clinical Trial
EU CTIS ID: 2025-522135-34-00
What this study is testing
To investigate the efficacy of a bilateral superficial parasternal intercostal plane (SPIP) block in the postoperative recovery of patients undergoing cardiac surgery via conventional median sternotomy.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- At least 18 years of age at the time of signing the Informed Consent Form
- Patients scheduled for cardiac surgery via conventional median sternotomy.
- Patients with an European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2 ≤ 3 %.
- Dutch speaking
You likely can't join if
- Participation in an interventional Trial with an investigational medicinal product (IMP) or device
- BMI > 35
- Patients with a bodyweight below 50 kg or exceeding 95 kg.
- An adult who is incapable or unable to give consent (e.g. curatorship, guardianship, language barrier,…).
- Patients requiring emergency surgery within 24 hours.
- Patients with chronic pain (i.e., chronic opioid use or other analgesics)
See the full eligibility criteria
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- At least 18 years of age at the time of signing the Informed Consent Form
- Patients scheduled for cardiac surgery via conventional median sternotomy.
- Patients with an European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2 ≤ 3 %.
- Dutch speaking
- Participation in an interventional Trial with an investigational medicinal product (IMP) or device
- BMI > 35
- Patients with a bodyweight below 50 kg or exceeding 95 kg.
- An adult who is incapable or unable to give consent (e.g. curatorship, guardianship, language barrier,…).
- Patients requiring emergency surgery within 24 hours.
- Patients with chronic pain (i.e., chronic opioid use or other analgesics)
- Any disorder or medical condition, which in the principle investigator’s opinion, would jeopardise the patient’s safety or compliance with the trial. (allergies, concomitant drugs that interact with the IMP
- If applicable: Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. Women of child-bearing potential (WOCBP) should only be included after a confirmed menstrual period and urinary pregnancy test. Participants are considered not of childbearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal, defined as no menses for 12 months without an alternative medical cause.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.